portal hypertension
Conditions
Interventions
Group A treatment group:Carvedilol was taken orally in the treatment group,
Group A control group:while carvedilol was not used in the control group. [When patients in the control group of group A experienced recurrent portal hypertension complications, they were directly tra
Group B treatment group:Carvedilol was taken orally in treatment group
Group B control group: propranolol in control group.
Sponsors
The First Affiliated Hospital of Xinjiang Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 59 Years
Inclusion criteria
Inclusion criteria: (1) The patient must sign the informed consent and voluntarily accept the follow-up. (2) Patients treated with TIPS for portal hypertension due to cirrhosis and/or other causes. (3) Preoperative and postoperative portal vein pressure was measured during TIPS implantation, and the PPG after TIPS was still greater than 12 mmHg, or the PPG after TIPS was reduced by =50% compared with that before surgery, and the data records were complete. (4) Progression or recurrence of portal-hypertension-related complications still existed after TIPS.
Exclusion criteria
Exclusion criteria: (1) Observers unwilling or unable to perform regular follow-up. (2) Non-selective beta-blockers cannot be used or drug intolerance exists due to contraindications (such as bradycardia, atrioventricular block, asthma, etc.) (3) In the investigator's opinion, there are any other factors that are not suitable for inclusion or affect participants' participation in or completion of the trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Recurrence rate of portal hypertension complications; | — |
Secondary
| Measure | Time frame |
|---|---|
| Drug treatment target achievement rate; | — |
Countries
China
Contacts
Public ContactSun Lihua
The First Affiliated Hospital of Xinjiang Medical University
Outcome results
None listed